MRI Can Detect Early Stages of Alzheimer's Disease
the Psychiatry Advisor take:
Researchers at Northwestern University have developed a new, noninvasive magnetic resonance imaging probe that they say can identify the start of Alzheimer’s disease years before symptoms appear.
William L. Klein, PhD, of Northwestern’s Department of Neurobiology, and colleagues say that the MRI probe, which combines a magnetic nanostructure with an antibody that looks for toxic beta-amyloid oligomers in the brain, can detect Alzheimer’s early. Beta-amyloid, considered a hallmark of the disease, show up as dark areas in MRI scans of the brain, due to associated magnetic nanostructures, the researchers reported in the journal Nature Nanotechnology.
In brains with Alzheimer’s, beta-amyloid oligomers attack synapses of neurons, which harms memory and leads to the death of neurons. Over time, beta-amyloid builds up and sticks together, forming plaque. Oligomers, however, appear much earlier than the plaques — up to 10 years beforehand.
“Using MRI, we can see the toxins attached to neurons in the brain” Klein said in a statement. “We expect to use this tool to detect this disease early and to help identify drugs that can effectively eliminate the toxin and improve health.”
“This MRI method could be used to determine how well a new drug is working,” Vinayak P. Dravid, also of Northwestern, added. “If a drug is effective, you would expect the amyloid beta signal to go down.”
MRI Can Detect Early-Stage Alzheimer's Disease
Alzheimer's disease can be identified much before you see the usual symptoms, says a Northwestern University team of scientists and engineers. The team has invented a noninvasive magnetic resonance imaging device, which coupled a magnetic nanostructure with an "antibody that seeks out the amyloid beta brain toxins," going on to the beginning of Alzheimer's disease.
The MRI scans of the brain can detect the toxins that have gathered as dark areas, due to the associated magnetic nanostructures. A new brain imaging method to identify the toxin leading to Alzheimer's disease is available now, according to neuroscientist William L. Klein, leader of the research team, along with materials scientist Vinayak P. Dravid.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Should Physicians Treat Family and Friends? Three Experts Weigh In
- Predictors of Long-term Medication Adherence in Children With ADHD
- Influence of Psychostimulants on BMI and Height in Youth With ADHD
- Medication Adherence Predictors in Patients With Severe Psychiatric Disorders
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Substance Abuse and Primary Psychosis: A Closer Look
- SSRI Dose Increase Not Recommended for Antidepressant Treatment Failure
- Perimenstrual Symptom Exacerbation Observed in Borderline Personality Disorder
- Dialectical Behavior Therapy Effective in Reducing Suicide Attempts, Self-Harm in Adolescents
- Good Sleep Tied to Better Cardiometabolic Health in Youths
- Public Support Only Moderate for Opioid Harm Reduction Strategies